Design of Trials to Assess Safety and Effectiveness in Rx of CHF

  • Robert Temple
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 75)


It is a propitious time to consider drugs for the treatment of congestive heart failure (CHF). There is at present a great deal of academic and commercial interest in such agents, perhaps reflecting an early success, Captopril, and a partial success, amrinone IV, after a good deal of ambiguity and failure with prazosin and the beta agonists. Yet there is still a great deal to be learned. We do not yet know how much it is possible to achieve or what hemodynamic or exercise responses to drugs correspond best to clinically meaningful improvement.


Congestive Heart Failure Exercise Tolerance Filling Pressure Beta Agonist Vasospastic Angina 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Martinus Nijhoff Publishing, Boston 1987

Authors and Affiliations

  • Robert Temple
    • 1
  1. 1.Office of Drug Research & ReviewFood and Drug AdministrationUSA

Personalised recommendations